Asset Details
Do you wish to reserve the book?
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Do you wish to request the book?
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
2025
Overview
Cutaneous squamous cell carcinoma (cSCC) incidence and deaths continue to rise, underscoring the need for improved cSCC prevention. Elimination of actinic keratosis (AK) precursor lesions is a major strategy to prevent cSCC. Topical calcipotriol and 5-fluorouracil (5-FU) have been shown to eliminate AKs and reduce the risk of cSCC development, but the mechanism was undefined. In this issue of the JCI, Oka et al. demonstrate that type 2 immunity is necessary and sufficient for the elimination of premalignant keratinocytes and cSCC prevention. Paired biopsies from AK lesions and unaffected skin revealed that only keratinocytes from AKs produced thymic stromal lymphopoietin (TSLP) and damage-associated molecular patterns, resulting in selective recruitment of Th2 cells to the AK lesion. In mouse models of skin carcinogenesis, TSLP was necessary to recruit Th2 cells and trigger IL-24-mediated keratinocyte cell death. These findings suggest that the TSLP/Th2/IL-24 axis is a potential therapeutic target for SCC prevention.
Publisher
American Society for Clinical Investigation
Subject
/ Animals
/ Biopsy
/ Calcitriol - analogs & derivatives
/ Carcinoma, Squamous Cell - immunology
/ Carcinoma, Squamous Cell - pathology
/ Carcinoma, Squamous Cell - prevention & control
/ Humans
/ Immunity
/ Keratosis, Actinic - immunology
/ Keratosis, Actinic - pathology
/ Keratosis, Actinic - prevention & control
/ Lesions
/ Melanoma
/ Mice
/ Mutation
/ Skin Neoplasms - prevention & control
/ Thymic Stromal Lymphopoietin
/ Thymus
/ Tumors
